Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118276) titled 'An exploratory study on the combination of evoximab and SKB264 for neoadjuvant therapy of resectable esophageal cancer' on Feb. 3.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The Second Affiliated Hospital of Air Force Military Medical University
Condition:
ESCC
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-12
Target Sample Size: Experimental Group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=309052
Disclaimer: Curated by HT Syndication....